Genovis AB (publ.) (GENO) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.059x

Based on the latest financial reports, Genovis AB (publ.) (GENO) has a cash flow conversion efficiency ratio of 0.059x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr15.90 Million ≈ $1.71 Million USD) by net assets (Skr271.52 Million ≈ $29.22 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See GENO net asset quality index to measure how much of total assets are equity-financed.

Genovis AB (publ.) - Cash Flow Conversion Efficiency Trend (2008–2025)

This chart illustrates how Genovis AB (publ.)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check GENO operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.

Genovis AB (publ.) Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Genovis AB (publ.) ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Compañía Minera Autlán S.A.B. de C.V MX:AUTLANB	0.022x
Wasko S.A. WAR:WAS	0.045x
Yg Plus Inc KO:037270	0.143x
Wah Seong Corporation Bhd KLSE:5142	0.056x
Libstar Holdings Ltd JSE:LBR	0.068x
Panatlântica S.A SA:PATI3	0.069x
Military Insurance Corp VN:MIG	N/A
Teo Seng Capital Bhd KLSE:7252	0.029x

Annual Cash Flow Conversion Efficiency for Genovis AB (publ.) (2008–2025)

The table below shows the annual cash flow conversion efficiency of Genovis AB (publ.) from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see GENO market cap.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr271.52 Million ≈ $29.22 Million	Skr32.02 Million ≈ $3.45 Million	0.118x	-27.56%
2024-12-31	Skr227.97 Million ≈ $24.53 Million	Skr37.12 Million ≈ $3.99 Million	0.163x	-54.15%
2023-12-31	Skr190.81 Million ≈ $20.53 Million	Skr67.75 Million ≈ $7.29 Million	0.355x	+4908.05%
2022-12-31	Skr125.65 Million ≈ $13.52 Million	Skr-927.95K ≈ $-99.86K	-0.007x	-101.83%
2021-12-31	Skr113.99 Million ≈ $12.27 Million	Skr45.92 Million ≈ $4.94 Million	0.403x	+835.02%
2020-12-31	Skr87.17 Million ≈ $9.38 Million	Skr3.76 Million ≈ $404.12K	0.043x	-88.31%
2019-12-31	Skr35.62 Million ≈ $3.83 Million	Skr13.13 Million ≈ $1.41 Million	0.368x	+868.80%
2018-12-31	Skr26.07 Million ≈ $2.81 Million	Skr-1.25 Million ≈ $-134.48K	-0.048x	+89.57%
2017-12-31	Skr18.19 Million ≈ $1.96 Million	Skr-8.36 Million ≈ $-899.14K	-0.459x	+55.57%
2016-12-31	Skr15.55 Million ≈ $1.67 Million	Skr-16.08 Million ≈ $-1.73 Million	-1.034x	+43.40%
2015-12-31	Skr8.82 Million ≈ $949.39K	Skr-16.12 Million ≈ $-1.73 Million	-1.827x	-20.06%
2014-12-31	Skr14.58 Million ≈ $1.57 Million	Skr-22.19 Million ≈ $-2.39 Million	-1.522x	-303.82%
2013-12-31	Skr33.09 Million ≈ $3.56 Million	Skr-12.47 Million ≈ $-1.34 Million	-0.377x	+65.40%
2012-12-31	Skr13.63 Million ≈ $1.47 Million	Skr-14.85 Million ≈ $-1.60 Million	-1.089x	-61.46%
2011-12-31	Skr18.01 Million ≈ $1.94 Million	Skr-12.15 Million ≈ $-1.31 Million	-0.675x	+2.00%
2010-12-31	Skr15.23 Million ≈ $1.64 Million	Skr-10.48 Million ≈ $-1.13 Million	-0.688x	+45.43%
2009-12-31	Skr10.86 Million ≈ $1.17 Million	Skr-13.70 Million ≈ $-1.47 Million	-1.261x	+49.75%
2008-12-31	Skr6.68 Million ≈ $718.56K	Skr-16.76 Million ≈ $-1.80 Million	-2.510x	--

About Genovis AB (publ.)

ST:GENO Sweden Biotechnology

Market Cap

$135.93 Million

Skr1.26 Billion SEK

Market Cap Rank

#17971 Global

#308 in Sweden

Share Price

Skr19.12

Change (1 day)

-2.35%

52-Week Range

Skr16.16 - Skr27.10

All Time High

Skr87.00